Networking, partnering and debating critical issues: BioEurope: Basel, Switzerland, March 2023 BioEquity Dublin, Ireland May 2023 –Presenter Bio International Convention, Boston, MA, June 202 Jeffries Global Healthcare Conference, New York, NY June 2023
FIBROCOR WAS FOUNDED IN 2017 BY TORONTO INNOVATION ACCELERATION PARTNERS (TIAP) AND EVOTEC INT’L to develop the translational science capabilities coming from laboratories at St. Michael’s Hospital in Toronto, Canada. Leveraging a tissues biopsy collection […]
Oct 1, 2021 For Immediate Release – Fibrocor Therapeutics Inc, a precision medicine company developing first in class drugs for IPF and other fibrotic diseases, is participating at the upcoming Piper Sandler Lung Day conference […]
Fibrocor is pleased to be presenting at TSX Life Sciences Investor Day
TORONTO, CANADA / ACCESSWIRE / OCTOBER 27, 2020 – Fibrocor Therapeutics Inc. (“Fibrocor” or “the Company”), a privately held developer of de novo therapeutics to treat Fibrosis, announced today the appointment of industry veteran William […]
Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos […]
Mechelen, Belgium; December 2018, 22.01 CET – Fibrocor Therapeutics L.P. (Fibrocor), a privately held Canadian company, and Galapagos NV (Euronext & NASDAQ: GLPG) announced a global partnership focused on a novel target for idiopathic pulmonary […]